Soon after leaving the hospital, we started G3 Therapeutics (www.g3therapeutics.com) in 2012 after spending 15 years in academic medicine and preventive cardiology. The vision of G3 Therapeutics was to drastically and dramatically change and disrupt how we discover and develop new medicines. It took us about 10 years and over $45M to build our platform and technology in carefully designed clinical trials. We worked with the leading genomic companies, leading proteomics companies and leading metabolomics companies.

 

Our technology and platform were recognized as the deepest and most comprehensive Big Data and AI platform in cardiovascular disease. We discovered new blood tests and new medications for heart disease (see additional press release and publications here). Top 15 Big Pharma companies, such as Sanofi and Novartis turned to us for collaborations to further the discovery and development of novel, breakthrough medications. In 2019, we took our first step to move our focus toward health, wellness and longevity, by creating a joint venture with Juvenescence, a pioneer in anti-aging and longevity.

 

We recognized in 2022 that this platform is much more broadly applicable than just cardiovascular drug discovery and drug development. We started B4X Therapeutics to take a similar, comprehensive approach to devastating degenerative diseases of the brain (www.b4xtherapeutics.com). B4X Therapeutics was initially incubated and supported at the Illumina Accelerator in Foster City, CA.

 

The final step was to start PUER to use these technologies developed in our biotech companies to unravel, understand, and unbind factors that drive health, wellness, and longevity.

 

Welcome to Biology Unbound.